Hydroxychloroquine as a primary prophylactic agent against SARS-CoV-2 infection: A cohort study
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Hydroxychloroquine as a primary prophylactic agent against SARS-CoV-2 infection : A cohort study. / Kamstrup, Peter; Sivapalan, Pradeesh; Eklöf, Josefin; Hoyer, Nils; Ulrik, Charlotte Suppli; Pedersen, Lars; Lapperre, Therese S.; Harboe, Zitta Barrella; Bodtger, Uffe; Bojesen, Rasmus Dahlin; Håkansson, Kjell E.J.; Tidemandsen, Casper; Armbruster, Karin; Browatzki, Andrea; Meteran, Howraman; Meyer, Christian Niels; Skaarup, Kristoffer Grundtvig; Lassen, Mats Christian Højbjerg; Lundgren, Jens D.; Biering-Sørensen, Tor; Jensen, Jens Ulrik.
I: International Journal of Infectious Diseases, Bind 108, 2021, s. 370-376.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Hydroxychloroquine as a primary prophylactic agent against SARS-CoV-2 infection
T2 - A cohort study
AU - Kamstrup, Peter
AU - Sivapalan, Pradeesh
AU - Eklöf, Josefin
AU - Hoyer, Nils
AU - Ulrik, Charlotte Suppli
AU - Pedersen, Lars
AU - Lapperre, Therese S.
AU - Harboe, Zitta Barrella
AU - Bodtger, Uffe
AU - Bojesen, Rasmus Dahlin
AU - Håkansson, Kjell E.J.
AU - Tidemandsen, Casper
AU - Armbruster, Karin
AU - Browatzki, Andrea
AU - Meteran, Howraman
AU - Meyer, Christian Niels
AU - Skaarup, Kristoffer Grundtvig
AU - Lassen, Mats Christian Højbjerg
AU - Lundgren, Jens D.
AU - Biering-Sørensen, Tor
AU - Jensen, Jens Ulrik
N1 - Publisher Copyright: © 2021 The Authors
PY - 2021
Y1 - 2021
N2 - Objective: Hydroxychloroquine has been proposed as a primary prophylactic agent against coronavirus disease 2019 (COVID-19). This study aimed to investigate if patients treated with hydroxychloroquine for a non-COVID-19 indication had a lower risk of verified infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) compared with matched controls. Methods: A cohort comprising all persons in Denmark collecting hydroxychloroquine prescriptions in 2020 and 2019 (i.e., both during and before SARS-CoV-2 was confirmed in Denmark), matched by age and sex with controls, was studied. Data were collected using the Danish national registries, which contain complete information on patient health data, prescriptions and microbiological test results. The main outcome was microbiologically verified SARS-CoV-2 infection. Results: In total, 5488 hydroxychloroquine users were matched with 54,486 non-users. At baseline, the groups differed in terms of diagnoses of pulmonary disease, cardiovascular disease, renal disease, gastrointestinal/metabolic disease and dementia, as well as treatment with antirheumatic drugs. The final model was adjusted for these potential confounders. Use of hydroxychloroquine for non-COVID-19 indications was not associated with any change in confirmed SARS-CoV-2 (hazard ratio 0.90, 95% confidence interval 0.76–1.07). This result was robust in the propensity-score-matched sensitivity analysis. Conclusion: This study, which is the largest to date to investigate the primary prophylactic effect of hydroxychloroquine against SARS-CoV-2, does not support any prophylactic benefit of hydroxychloroquine in the prevention of infection with SARS-CoV-2.
AB - Objective: Hydroxychloroquine has been proposed as a primary prophylactic agent against coronavirus disease 2019 (COVID-19). This study aimed to investigate if patients treated with hydroxychloroquine for a non-COVID-19 indication had a lower risk of verified infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) compared with matched controls. Methods: A cohort comprising all persons in Denmark collecting hydroxychloroquine prescriptions in 2020 and 2019 (i.e., both during and before SARS-CoV-2 was confirmed in Denmark), matched by age and sex with controls, was studied. Data were collected using the Danish national registries, which contain complete information on patient health data, prescriptions and microbiological test results. The main outcome was microbiologically verified SARS-CoV-2 infection. Results: In total, 5488 hydroxychloroquine users were matched with 54,486 non-users. At baseline, the groups differed in terms of diagnoses of pulmonary disease, cardiovascular disease, renal disease, gastrointestinal/metabolic disease and dementia, as well as treatment with antirheumatic drugs. The final model was adjusted for these potential confounders. Use of hydroxychloroquine for non-COVID-19 indications was not associated with any change in confirmed SARS-CoV-2 (hazard ratio 0.90, 95% confidence interval 0.76–1.07). This result was robust in the propensity-score-matched sensitivity analysis. Conclusion: This study, which is the largest to date to investigate the primary prophylactic effect of hydroxychloroquine against SARS-CoV-2, does not support any prophylactic benefit of hydroxychloroquine in the prevention of infection with SARS-CoV-2.
KW - COVID-19
KW - Epidemiology
KW - Hydroxychloroquine
KW - Prophylaxis
KW - SARS-CoV-2
U2 - 10.1016/j.ijid.2021.05.076
DO - 10.1016/j.ijid.2021.05.076
M3 - Journal article
C2 - 34087484
AN - SCOPUS:85108262349
VL - 108
SP - 370
EP - 376
JO - International Journal of Infectious Diseases
JF - International Journal of Infectious Diseases
SN - 1201-9712
ER -
ID: 273644613